Cargando…

Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer

BACKGROUND: Ovarian cancer (OC) is the leading cause of gynecologic malignant tumors. The role of necroptosis-related lncRNAs (NRLs) in OC remains unclear. This study aims to explore the association between NRLs and prognosis in OC patients. METHODS: The Cancer Genome Atlas (TCGA) and GTEx datasets...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Linling, He, Jiaoyan, Yang, Xinyun, Zheng, Jianfeng, Liu, Wenhua, Chen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152429/
https://www.ncbi.nlm.nih.gov/pubmed/35656337
http://dx.doi.org/10.1155/2022/6228846
_version_ 1784717645871841280
author Zhu, Linling
He, Jiaoyan
Yang, Xinyun
Zheng, Jianfeng
Liu, Wenhua
Chen, Hao
author_facet Zhu, Linling
He, Jiaoyan
Yang, Xinyun
Zheng, Jianfeng
Liu, Wenhua
Chen, Hao
author_sort Zhu, Linling
collection PubMed
description BACKGROUND: Ovarian cancer (OC) is the leading cause of gynecologic malignant tumors. The role of necroptosis-related lncRNAs (NRLs) in OC remains unclear. This study aims to explore the association between NRLs and prognosis in OC patients. METHODS: The Cancer Genome Atlas (TCGA) and GTEx datasets were used to obtain OC's data. A NRLs signature associated with overall survival (OS) was constructed by Cox-LASSO regression analysis in training cohort for calculating risk score and then validated in testing cohort. Subsequently, the area under the curve (AUC) and Kaplan–Meier survival analysis were used to evaluate the predictive accuracy of the risk score. Finally, the immune infiltration and functional enrichment were compared between different risk groups. RESULTS: A 8-NRLs signature including AC245128.3, AL355488.1, AC092794.1, AC068888.2, AL590652.1, AC008982.2, FOXP4-AS1, and Z94721.1 was identified to assess the OS of OC. Kaplan–Meier survival analysis, AUC value, and Cox regression analysis confirmed its predictive value and showed that the clinical outcomes were worse for high-risk patients. There were also differences in immunological functioning and immune pathways between the high-risk and low-risk groups. CONCLUSIONS: The signature based on eight NRLs has significant values in predicting prognostic prediction in OC, as well as providing a new sight for targeted therapies.
format Online
Article
Text
id pubmed-9152429
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-91524292022-06-01 Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer Zhu, Linling He, Jiaoyan Yang, Xinyun Zheng, Jianfeng Liu, Wenhua Chen, Hao J Oncol Research Article BACKGROUND: Ovarian cancer (OC) is the leading cause of gynecologic malignant tumors. The role of necroptosis-related lncRNAs (NRLs) in OC remains unclear. This study aims to explore the association between NRLs and prognosis in OC patients. METHODS: The Cancer Genome Atlas (TCGA) and GTEx datasets were used to obtain OC's data. A NRLs signature associated with overall survival (OS) was constructed by Cox-LASSO regression analysis in training cohort for calculating risk score and then validated in testing cohort. Subsequently, the area under the curve (AUC) and Kaplan–Meier survival analysis were used to evaluate the predictive accuracy of the risk score. Finally, the immune infiltration and functional enrichment were compared between different risk groups. RESULTS: A 8-NRLs signature including AC245128.3, AL355488.1, AC092794.1, AC068888.2, AL590652.1, AC008982.2, FOXP4-AS1, and Z94721.1 was identified to assess the OS of OC. Kaplan–Meier survival analysis, AUC value, and Cox regression analysis confirmed its predictive value and showed that the clinical outcomes were worse for high-risk patients. There were also differences in immunological functioning and immune pathways between the high-risk and low-risk groups. CONCLUSIONS: The signature based on eight NRLs has significant values in predicting prognostic prediction in OC, as well as providing a new sight for targeted therapies. Hindawi 2022-05-23 /pmc/articles/PMC9152429/ /pubmed/35656337 http://dx.doi.org/10.1155/2022/6228846 Text en Copyright © 2022 Linling Zhu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhu, Linling
He, Jiaoyan
Yang, Xinyun
Zheng, Jianfeng
Liu, Wenhua
Chen, Hao
Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer
title Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer
title_full Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer
title_fullStr Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer
title_full_unstemmed Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer
title_short Derivation and Validation of a Necroptosis-Related lncRNA Signature in Patients with Ovarian Cancer
title_sort derivation and validation of a necroptosis-related lncrna signature in patients with ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152429/
https://www.ncbi.nlm.nih.gov/pubmed/35656337
http://dx.doi.org/10.1155/2022/6228846
work_keys_str_mv AT zhulinling derivationandvalidationofanecroptosisrelatedlncrnasignatureinpatientswithovariancancer
AT hejiaoyan derivationandvalidationofanecroptosisrelatedlncrnasignatureinpatientswithovariancancer
AT yangxinyun derivationandvalidationofanecroptosisrelatedlncrnasignatureinpatientswithovariancancer
AT zhengjianfeng derivationandvalidationofanecroptosisrelatedlncrnasignatureinpatientswithovariancancer
AT liuwenhua derivationandvalidationofanecroptosisrelatedlncrnasignatureinpatientswithovariancancer
AT chenhao derivationandvalidationofanecroptosisrelatedlncrnasignatureinpatientswithovariancancer